Implanet SA (ALIMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Implanet SA (ALIMP) has a cash flow conversion efficiency ratio of -0.700x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-283.00K ≈ $-330.86K USD) by net assets (€404.00K ≈ $472.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALIMP stock market capitalisation for the company's overall valuation and market capitalisation.
Implanet SA - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Implanet SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Implanet SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Implanet SA ranked by their cash flow conversion efficiency. See Implanet SA cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
-0.032x |
|
Megachem (Thailand) Public Company Limited
BK:MGT
|
0.034x |
|
Pico (Thailand) Public Company Limited
BK:PICO
|
-0.070x |
|
Korea Eng Cons
KO:023350
|
-0.096x |
|
IFS Capital (Thailand) Public Company Limited
BK:IFS
|
-0.101x |
|
Arvee Laboratories (India) Limited
NSE:ARVEE
|
0.043x |
|
Borealis Foods Inc.
NASDAQ:BRLS
|
0.015x |
|
Impero AS
CO:IMPERO
|
-1.696x |
Annual Cash Flow Conversion Efficiency for Implanet SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Implanet SA from 2012 to 2025. View latest Implanet SA stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €404.00K ≈ $472.32K |
€-589.00K ≈ $-688.60K |
-1.458x | +54.39% |
| 2024-12-31 | €727.00K ≈ $849.94K |
€-2.32 Million ≈ $-2.72 Million |
-3.197x | -138.44% |
| 2023-12-31 | €-174.00K ≈ $-203.42K |
€-1.45 Million ≈ $-1.69 Million |
8.316x | +1324.93% |
| 2022-12-31 | €3.54 Million ≈ $4.14 Million |
€-2.40 Million ≈ $-2.81 Million |
-0.679x | +45.84% |
| 2021-12-31 | €2.80 Million ≈ $3.28 Million |
€-3.52 Million ≈ $-4.11 Million |
-1.254x | +58.26% |
| 2020-12-31 | €1.02 Million ≈ $1.19 Million |
€-3.07 Million ≈ $-3.59 Million |
-3.003x | -53.51% |
| 2019-12-31 | €1.44 Million ≈ $1.68 Million |
€-2.81 Million ≈ $-3.28 Million |
-1.956x | -5.80% |
| 2018-12-31 | €2.40 Million ≈ $2.81 Million |
€-4.44 Million ≈ $-5.19 Million |
-1.849x | -160.38% |
| 2017-12-31 | €6.29 Million ≈ $7.35 Million |
€-4.46 Million ≈ $-5.22 Million |
-0.710x | -16.42% |
| 2016-12-31 | €9.66 Million ≈ $11.29 Million |
€-5.89 Million ≈ $-6.89 Million |
-0.610x | +12.91% |
| 2015-12-31 | €9.73 Million ≈ $11.37 Million |
€-6.81 Million ≈ $-7.96 Million |
-0.700x | +4.55% |
| 2014-12-31 | €7.21 Million ≈ $8.43 Million |
€-5.29 Million ≈ $-6.19 Million |
-0.734x | -88.93% |
| 2013-12-31 | €13.87 Million ≈ $16.21 Million |
€-5.39 Million ≈ $-6.30 Million |
-0.388x | +54.44% |
| 2012-12-31 | €4.68 Million ≈ $5.47 Million |
€-3.99 Million ≈ $-4.66 Million |
-0.852x | -- |
About Implanet SA
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-… Read more